Semglee's Boost On Express Scripts Formulary Reflects Interchangeability – And Rebates
Viatris’s Insulin Biosimilar Gets Preferred Status
Executive Summary
First interchangeable insulin biosimilar gains preferred status on one of the largest national formularies in the US.
You may also be interested in...
Viatris Wins Landmark First US Interchangeability Designation For Semglee
Viatris has revealed its commercial strategy for its Semglee insulin glargine biosimilar in the US after winning a landmark first designation of interchangeability for the product from the FDA that will allow pharmacy-level substitution with a year of exclusivity.
Express Scripts Insulin Program Lowers Cost Sharing With Supplemental Manufacturer Discounts
New wrinkle on lowering out-of-pocket spending differs from point-of-sale rebates and manufacturer copay assistance cards, the PBM says, and is not expected to increase plan costs.
Real-World Evidence Registry Aims To Build Research Credibility Through Transparency
Pre-registration of study protocols will be voluntary and concerns with revealing proprietary information, among other issues, could be a deterrent to participation. But the developers of the registry hope that researchers will conclude the benefits of doing so outweigh the risks.